London: GSK plc has announced that the US Food and Drug Administration (FDA) has accepted for review an application to extend the indication of Arexvy (respiratory syncytial virus (RSV) ...

GSK plc (LSE/NYSE: GSK) announced its sponsorship of the 2025 National Senior Games as part of its nationwide Sideline RSV campaign, a health education campaign aimed at helping educate older adults ...

GSK sponsors the 2025 National Senior Games to raise awareness about RSV risks and prevention for older adults through education and athlete stories.

British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...

GSK plc has announced its sponsorship of the 2025 National Senior Games as part of its Sideline RSV campaign, a nationwide health education initiative aimed at informing adults ...

Expanded age indication for GSK’s AREXVY, the first respiratory syncytial virus (RSV) vaccine approved in Canada for adults aged 50-59 at increased risk (CNW Group/GlaxoSmithKline Inc.) ...

The GSK proprietary AS01 adjuvant system contains QS-21 Stimulon adjuvant licensed from Antigenics Inc, a wholly owned subsidiary of Agenus Inc. About respiratory syncytial virus (RSV) ...

Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time The approval is based on data from the positive pivotal AReSVi-006 phase III trial ...

(Reuters) -British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing it of violating GSK patent rights in messenger RNA technology with its blockbuster ...

LONDON — Data unveiled on Thursday showed GSK’s respiratory syncytial virus (RSV) vaccine was 82.6% effective in a keenly watched late-stage study involving older adults. RSV is a leading cause of ...

The application is supported by positive results from a phase III trial [NCT05590403] 4 evaluating the immune response and safety of GSK’s RSV vaccine in adults aged 50-59, including ...

In the US, AREXVY is indicated for the prevention of RSV-LRTD in individuals 60 years of age and older. GSK’s RSV older adult vaccine is not currently approved anywhere outside the US.